SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2010; 60: 277-300.
  • 2
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resented colon carcinoma. N Engl J Med. 1990; 322: 352-358.
  • 3
    O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997; 15: 246-250.
  • 4
    Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993; 11: 1879-1887.
  • 5
    Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22: 3408-3419.
  • 6
    Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005; 23: 8671-8678.
  • 7
    Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005; 352: 2696-2704.
  • 8
    Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project protocol C-06. J Clin Oncol. 2006; 24: 2059-2064.
  • 9
    André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
  • 10
    de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol. 2005; 23( 16S). Abstract 3501.
  • 11
    Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204.
  • 12
    André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol. 2009; 27: 3109-3116.
  • 13
    Centers for Disease Control and Prevention (CDC). Cancer survivors—United States, 2007. MMWR. 2011; 60: 269-272.
  • 14
    Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 including survival and subset analyses. J Clin Oncol. 2011; 29: 3768-3774.
  • 15
    Kopec JA, Land SR, Cecchini RS, et al. Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin [serial online]. J Support Oncol. 2006; 4: W1-W8. Available at: http://www.supportiveoncology.net/jso/journal/abstracts/0408396.html. Accessed November 29, 2011.
  • 16
    Yothers G, O'Connell MJ, Colangelo L, et al. 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: long-term follow-up of NSABP C-07 with survival analysis [abstract]. Paper presented at: ASCO Gastrointestinal Cancers Symposium; Orlando, FL; January 22-24, 2010. Abstract 401.
  • 17
    Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007; 25: 2205-2211.
  • 18
    Ganz P, Land SR, Antonio C, et al. Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv. 2009; 3: 137-147.
  • 19
    National Cancer Institute (NCI). NCI Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4–30-992.pdf. Accessed November 29, 2011.
  • 20
    Kuroi K, Shimozuma K. Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer. 2004; 11: 92-99.
  • 21
    Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of taxane therapy in oncology: the Functional Assessment of Cancer Therapy-taxane (FACT-taxane). Cancer. 2003; 98: 822-831.
  • 22
    Kunitake H, Zheng P, Yothers G, et al. Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol LTS-01. J Clin Oncol. 2010; 28: 5274-5279.
  • 23
    Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011; 16: 708-716.
  • 24
    Mold JW, Vesely SK, Keyl BA, et al. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract. 2004; 17: 309-318.
  • 25
    Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29: 1465-1471.
  • 26
    Park SB, Lin CS-Y, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009; 132: 2712-2723.
  • 27
    Boige V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010; 28: 2556-2564.
  • 28
    Park SB, Lin CS-Y, Krishnan AV, et al. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Exp Neurol. 2011; 227: 120-127.
  • 29
    Braun MS, Seymour MT. Molecular markers of chemotherapy toxicity in colorectal cancer. Curr Colorectal Cancer Rep. 2011; 7: 105-111.